Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 415

Document Document Title
WO/2021/061898A1
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for trea...  
WO/2021/032591A1
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in...  
WO/2021/032588A1
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds ...  
WO/2021/002473A1
The invention addresses the problem of providing a compound having Nrf2-activation action. The invention is the compound represented by general formula (I), a salt thereof, or a solvate thereof. General formula (I): In the formula: R1a a...  
WO/2020/254471A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.  
WO/2020/234483A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/221272A1
The present disclosure relates to an indole macrocyclic derivative, a preparation method therefor and use thereof in medicine. Specifically, the present disclosure relates to an indole macrocyclic derivative represented by general formul...  
WO/2020/206080A1
Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.  
WO/2020/185606A1
Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in tr...  
WO/2020/167984A1
Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compoun...  
WO/2020/151738A1
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth in the specification. Also provided c...  
WO/2020/147802A1
Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are a...  
WO/2020/138015A1
The present invention provides: a novel compound that is useful for treating or preventing infections associated with viruses belonging to the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), and that has an anti-RSV...  
WO/2020/103864A1
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I f...  
WO/2020/105068A1
The present invention relates to an improved and industrially viable process for the preparation of Trabectedin. The present invention also relates to an improved and industrially viable process for the preparation of Trabectedin Interme...  
WO/2020/097577A1
The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.  
WO/2020/090636A1
Provided are: a compound having excellent semiconductor characteristics; a method for producing the compound; an intermediate of the compound; a method for producing the intermediate; and an organic semiconductor material and an organic ...  
WO/2020/063792A1
The present invention relates to an indole macrocyclic derivative, a preparation method therefor and an application thereof in medicine. Specifically, the present invention relates to an indole macrocyclic derivative represented by gener...  
WO/2020/041169A3
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...  
WO/2020/050546A1
The present invention provides a compound represented by formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode, and an ...  
WO/2020/041169A2
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...  
WO/2020/030781A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/023560A1
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also de...  
WO/2020/016434A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2019/035914A8
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...  
WO/2019/161078A1
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...  
WO/2019/126730A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...  
WO/2019/114704A1
The present invention provides a preparation method for a natural product Trabectedin. Specifically, the present invention provides a preparation method for Et-743. In the method, tyrosine is used as an initial substrate, and after 26 st...  
WO/2019/097544A1
The invention provides a compound for specific detection of SLNPV. Further, the invention provides a probe for specific detection of SLNPV. The probe comprises of a substrate embedded with the compound. The invention also provides a kit ...  
WO/2019/079357A1
TNIK inhibitors, conjugates thereof, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in treating of cancer by modulating T...  
WO/2019/053617A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...  
WO/2019/035927A1
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...  
WO/2019/035914A1
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...  
WO/2019/035911A1
The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acc...  
WO/2019/035899A1
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acce...  
WO/2019/024809A1
A bicyclic compound acting as a RORγ inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compoun...  
WO/2019/007793A1
The invention relates to the technical field of herbicides and/or plant growth regulators. Specifically, the invention relates to novel isothiazolo-based bicycles, and compositions comprising said novel isothiazolo-based bicycles. Furthe...  
WO/2018/197663A1
A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.  
WO/2018/178226A1
Disclosed are Mcl-1 inhibitors, pharmaceutical compositions comprising the same and methods of using the same.  
WO/2018/153326A1
The present invention relates to a sulfonyl hydrazine compound and a use thereof as a medicament for use in treating hepatitis B. Specifically, the present invention discloses a compound which may act as an HBV inhibitor and which has th...  
WO/2018/108070A1
A compound comprises a donor and an acceptor, wherein at least one donor ( "D" ) and at least one acceptor ( "A" ) may be arranged in an order of D-A; D-A-D; A-D-A; D-D-A-D-D; A-A-D-A-A; D-A-D-A-D; and A-D-A-D-A. The compound may be sele...  
WO/2018/109643A1
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula...  
WO/2017/202340A1
Disclosed are a series of photoisomeric compounds, preparation method therefor and devices comprising the compounds, wherein a photoisomeric compound-graphene molecular junction device is formed by linking the photoisomeric compound to a...  
WO/2017/182625A1
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13 ,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030, 35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-ca rbo...  
WO/2017/147410A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharma...  
WO/2017/127820A1
Disclosed herein, in part, are compounds and methods for their use in the treatment of malaria. In at least one specific embodiment, the compounds or salts thereof can include compounds of Formula (I):  
WO/2017/105040A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure can provide an organic electrolumine...  
WO/2017/060167A1
The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular o...  
WO/2017/021805A1
The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salt...  
WO/2017/001655A1
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...  

Matches 1 - 50 out of 415